Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3534717rdf:typepubmed:Citationlld:pubmed
pubmed-article:3534717lifeskim:mentionsumls-concept:C0004613lld:lifeskim
pubmed-article:3534717lifeskim:mentionsumls-concept:C0035891lld:lifeskim
pubmed-article:3534717lifeskim:mentionsumls-concept:C0282563lld:lifeskim
pubmed-article:3534717lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3534717lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:3534717pubmed:issue5lld:pubmed
pubmed-article:3534717pubmed:dateCreated1986-12-4lld:pubmed
pubmed-article:3534717pubmed:abstractTextThe "in vitro" susceptibility to roxithromycin and three other macrolides of 236 anaerobes isolated from clinical samples in 1984/1985 was determined by an agar-dilution method on Wilkins Chalgren medium. 90% of Gram positive cocci were susceptible to both roxithromycin and josamycin (MIC less than 1 mg/l, whereas 1 mg/l erythromycin and 2 mg/l spiramycin were able to inhibit respectively 46 and 86% of the same tested strains. No resistance to the four macrolides was observed among Eubacterium, propionibacterium and Bifidobacterium. Two C. perfringens strains and one C. difficile strain were resistant to all four macrolides, while 97% of Clostridium sp. strains were inhibited by 4 mg/l erythromycin, josamycin or roxithromycin. Against Gram positive anaerobes, roxithromycin was equal or superior to erythromycin and spiramycin. At a concentration of 4 mg/l, roxithromycin inhibited 82% of B. fragilis strains. Roxithromycin and josamycin were more active against Gram negative bacilli that erythromycin and spiramycin. Macrolides had no effect on Fusobacterium strains. In this study, 4 mg/l roxithromycin inhibited 217 of the 236 anaerobic strains investigated (92%).lld:pubmed
pubmed-article:3534717pubmed:languagefrelld:pubmed
pubmed-article:3534717pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3534717pubmed:citationSubsetIMlld:pubmed
pubmed-article:3534717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3534717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3534717pubmed:statusMEDLINElld:pubmed
pubmed-article:3534717pubmed:monthMaylld:pubmed
pubmed-article:3534717pubmed:issn0369-8114lld:pubmed
pubmed-article:3534717pubmed:authorpubmed-author:BryskierAAlld:pubmed
pubmed-article:3534717pubmed:authorpubmed-author:RomondCClld:pubmed
pubmed-article:3534717pubmed:authorpubmed-author:DubreuilLLlld:pubmed
pubmed-article:3534717pubmed:authorpubmed-author:DevosJJlld:pubmed
pubmed-article:3534717pubmed:issnTypePrintlld:pubmed
pubmed-article:3534717pubmed:volume34lld:pubmed
pubmed-article:3534717pubmed:ownerNLMlld:pubmed
pubmed-article:3534717pubmed:authorsCompleteYlld:pubmed
pubmed-article:3534717pubmed:pagination440-4lld:pubmed
pubmed-article:3534717pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3534717pubmed:meshHeadingpubmed-meshheading:3534717-...lld:pubmed
pubmed-article:3534717pubmed:meshHeadingpubmed-meshheading:3534717-...lld:pubmed
pubmed-article:3534717pubmed:meshHeadingpubmed-meshheading:3534717-...lld:pubmed
pubmed-article:3534717pubmed:meshHeadingpubmed-meshheading:3534717-...lld:pubmed
pubmed-article:3534717pubmed:meshHeadingpubmed-meshheading:3534717-...lld:pubmed
pubmed-article:3534717pubmed:year1986lld:pubmed
pubmed-article:3534717pubmed:articleTitle[In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].lld:pubmed
pubmed-article:3534717pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3534717pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3534717pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:3534717pubmed:publicationTypeEnglish Abstractlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3534717lld:pubmed